article thumbnail

Axillary Hyperhidrosis Global Market Experiencing Significant Growth

MedEsthetics

global market report, axillary hyperhidrosis, underarm sweat, excessive sweating, botox, topical antiperspirants, FDA approval, US market size, clinical guidelines

Marketing 136
article thumbnail

U.S. FDA Clears Avita Medical’s Cohealyx for Healing Full-thickness Wounds

The Dermatology Digest

While animal model results do not necessarily translate to clinical results, this expedited timeline is anticipated to lead to quicker wound closure and streamlined clinician workflows, resulting in shorter hospital stays, reduced treatment costs, and better patient outcomes. These parameters will be evaluated in a clinical study.

article thumbnail

MHRA Grants Marketing Authorization for LEO Pharma’s CHE Cream in Great Britain

The Dermatology Digest

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for delgocitinib cream (Anzupgo, Leo Pharma) for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.

article thumbnail

The Growing Interest in Exosomes & Platelet-rich Plasma for Wound Healing

MedEsthetics

Platelet-rich plasma (PRP) and exosomes are becoming the gold standard for wound and scar healing, resulting in market growth and an increase in clinical research.

Scarring 147
article thumbnail

Body Hair Transplantation Offers Promising Potential in Hair Restoration

MedEsthetics

medical aesthetics, hair loss, market report, aesthetic devices, hair grow system, body hair transplantation, clinical trials, beard hair, body hair, scalp health

Marketing 146
article thumbnail

U.S. FDA Approves Celltrion’s STELARA Biosimilar

The Dermatology Digest

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. immunology market.” “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb). .

article thumbnail

Buoyed by New Data, Galderma’s Liquid Toxin Launches Across Europe

The Dermatology Digest

The neuromodulator also has marketing authorization from Australia’s Therapeutic Goods Administration and the Medicines and Healthcare Products Regulatory Agency in the UK. The European launch is further supported by new data from the Phase IIIb RELAX clinical trial that was presented at IMCAS. In the U.S., In the U.S.,